newsfilter
← Latest News
Business Wire·

Humanigen Launches Managed Access Program for Lenzilumab

Humanigen, Inc. (NASDAQ:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced today that lenzilumab is now available for certain hospitalized COVID-19 patients